Lineage Cell Therapeutics, Inc.
LCTX
$1.11
$0.032.78%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.87% | 54.64% | 53.24% | 24.05% | 76.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.87% | 54.64% | 53.24% | 24.05% | 76.43% |
| Cost of Revenue | 57.39% | 47.56% | 39.58% | -1.81% | -7.17% |
| Gross Profit | -166.73% | 25.40% | -0.36% | 50.09% | 72.59% |
| SG&A Expenses | 6.13% | 3.64% | 1.59% | 23.96% | 28.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.54% | 21.91% | 17.30% | 11.60% | 10.82% |
| Operating Income | -31.65% | -7.25% | -1.40% | -5.94% | 7.57% |
| Income Before Tax | 8.28% | -328.61% | -269.43% | -236.77% | -68.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.23% | -295.95% | -241.01% | -236.77% | -68.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.97% | -394.87% | -514.81% | -127.69% | -1,050.00% |
| Net Income | 21.14% | -296.19% | -241.41% | -236.42% | -69.14% |
| EBIT | -31.65% | -7.25% | -1.40% | -5.94% | 7.57% |
| EBITDA | -32.09% | -6.85% | -1.01% | -5.98% | 7.61% |
| EPS Basic | 22.71% | -256.05% | -189.79% | -169.28% | -35.07% |
| Normalized Basic EPS | -39.59% | -202.24% | -145.67% | -157.68% | -2.82% |
| EPS Diluted | -2.08% | -261.47% | -191.56% | -170.83% | -36.34% |
| Normalized Diluted EPS | -38.63% | -200.61% | -145.67% | -157.68% | -2.82% |
| Average Basic Shares Outstanding | 8.73% | 11.32% | 14.95% | 25.54% | 22.43% |
| Average Diluted Shares Outstanding | 11.91% | 13.23% | 14.95% | 25.54% | 22.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |